secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001193125-23-268875
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir Q3 net loss $44.3M ($0.39/sh); cash $213.3M funds trials to H2 2024 data
--------------------------------------------------------------------------------

- Net loss $44.3M vs $42.1M in Q3 2022; diluted EPS loss $0.39 vs $0.50.
- Cash, equivalents and short-term investments $213.3M at Sep 30, down from $233.8M at Dec 31, 2022.
- R&D expense $34.2M, up from $30.0M YoY, driven by posoleucel trial costs.
- Three Phase 3 posoleucel trials enrolling; topline data expected in H2 2024 for all three.
- FY 2023 operating expense guidance $150M-$170M, excluding non-cash items.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523268875/0001193125-23-268875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523268875/d559627d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-268875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer